Since the discovery of a linkage between GRKs and cardiovascular disease including hypertension and heart failure, GRKs—especially GRK2 and GRK4—have been considered pharmaceutical targets for the treatment of cardiovascular disease. This evidence concerns the gene GRK2 and heart failure.